Articles by Jill Wechsler - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jill Wechsler
« Previous
123456789101112
Next »

Celebrating 25 Years of Orphan Drugs

New scientific discoveries promise to expand treatments for rare and neglected diseases.
Jul 2, 2008
By: Jill Wechsler

New scientific discoveries promise to expand treatments for rare and neglected diseases.

Healthcare Reform Proposals Challenge Manufacturers

Comparative-effectiveness analysis aims to promote appropriate pharmaceutical spending.
Jun 2, 2008
By: Jill Wechsler

Comparative-effectiveness analysis aims to promote appropriate pharmaceutical spending.

Attacks on FDA Escalate

Regulators face demands to improve postmarket surveillance and meet review deadlines.
May 2, 2008
By: Jill Wechsler

Regulators face demands to improve postmarket surveillance and meet review deadlines.

FDA Inspection Program Under Scrutiny

Heparin contamination casts a shadow on regulatory oversight of product quality.
Apr 2, 2008
By: Jill Wechsler

Heparin contamination casts a shadow on regulatory oversight of product quality.

CDER Gains Woodcock as Permanent Chief

Mar 13, 2008
By: Jill Wechsler

Much to the surprise of most close observers of the Food and Drug Administration, Janet Woodcock agreed last month to resume control of the Center for Drug Evaluation and Research.

FDA Seeks Regulatory Flexibility

Quality-by-design submissions may reduce supplements and improve change management.
Mar 2, 2008
By: Jill Wechsler

Quality-by-design submissions may reduce supplements and improve change management.

Limited Resources, Expanding Imports Challenge Regulators

The rise in overseas manufacturing undermines FDA oversight of drug quality.
Feb 2, 2008
By: Jill Wechsler

The rise in overseas manufacturing undermines FDA oversight of drug quality.

Opportunities for 2008

As FDA implements new drug-safety policies, manufacturers will focus on quality and pricing.
Jan 2, 2008
By: Jill Wechsler

As FDA implements new drug-safety policies, manufacturers will focus on quality and pricing.

What's Next in: Strategy and Regulation

Dec 2, 2007
By: Maribel Rios, Jill Wechsler

There are at least two major factors that will shape the manufacturing industry as a whole. Daniel Ruppar, Industry Manager (North America) for the Pharmaceuticals and Biotechnology Division of Frost & Sullivan predicts that, due to continued globalization, we can expect to see "growth centers for the industry move to emerging market sectors."

« Previous
123456789101112
Next »

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here